A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions
Chronic Graft-Versus-Host Disease (cGVHD)
Interventions
DRUG

Vimseltinib

Administered orally

Trial Locations (23)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

23298

RECRUITING

Virginia Commonwealth University, Richmond

27705

RECRUITING

Duke University Hospital, Durham

28204

RECRUITING

Levine Cancer Institute, Charlotte

30322

RECRUITING

Emory University Winship Cancer Institute, Atlanta

32804

RECRUITING

AdventHealth Orlando, Orlando

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

Tristar Bone Marrow Transplant, Nashville

40536

RECRUITING

University of Kentucky Markey Cancer Center, Lexington

44195

RECRUITING

Cleveland Clinic, Cleveland

45242

RECRUITING

Oncology Hematology Care Clinical Trials, LLC, Cincinnati

48202

RECRUITING

Henry Ford Cancer Institute, Detroit

57105

RECRUITING

Avera Cancer Institute, Sioux Falls

60612

RECRUITING

University of Illinois Medical Center - Hematology & Oncology, Chicago

63108

RECRUITING

Washington University School of Medicine - Siteman Cancer Center, St Louis

66205

RECRUITING

University of Kansas Cancer Center-Westwood, Westwood

78704

RECRUITING

St. David's South Austin Medical Center, Austin

84143

RECRUITING

Intermountain Health, Salt Lake City

90095

RECRUITING

Ronald Regan UCLA Medical Center, Los Angeles

91010

RECRUITING

City of Hope National Medical Center, Duarte

97239

RECRUITING

Oregon Health and Science University, Portland

92868-3201

RECRUITING

University of California Irvine Health, Orange

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Deciphera Pharmaceuticals, LLC

INDUSTRY

NCT06619561 - A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | Biotech Hunter | Biotech Hunter